These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. Kim NH; Rubin LJ J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973 [TBL] [Abstract][Full Text] [Related]
26. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350 [TBL] [Abstract][Full Text] [Related]
28. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. ZacĂ V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198 [TBL] [Abstract][Full Text] [Related]